For the year ending 2025-12-31, NAGE has $106,406K in assets. $29,873K in debts.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents, including restricted cash of 152 for both periods presented | 64,788 | |||
| Trade receivables, net of allowances of 147 and 95, respectively | 9,741 | |||
| Inventories | 20,424 | |||
| Assets held for sale | 541 | |||
| Prepaid expenses and other assets | 1,312 | |||
| Total current assets | 96,806 | |||
| Leasehold improvements and equipment, net | 1,323 | |||
| Intangible assets, net | 5,660 | |||
| Right-of-use assets | 2,192 | |||
| Other long-term assets | 425 | |||
| Total assets | 106,406 | |||
| Accounts payable | 10,796 | |||
| Accrued expenses | 7,722 | |||
| Current maturities of operating lease obligations | 1,002 | |||
| Current maturities of finance lease obligations | 0 | |||
| Customer deposits | 399 | |||
| Total current liabilities | 19,919 | |||
| Deferred revenue | 2,674 | |||
| Operating lease obligations, less current maturities | 1,815 | |||
| Deferred consideration liability | 5,465 | |||
| Total liabilities | 29,873 | |||
| Common stock, 0.001 par value authorized 150,000 shares 79,714 shares and 77,330 shares issued and outstanding at december31, 2025 and december31, 2024, respectively | 79 | |||
| Additional paid-in capital | 240,991 | |||
| Accumulated deficit | -164,528 | |||
| Cumulative translation adjustments | -9 | |||
| Total stockholders' equity | 76,533 | |||
| Total liabilities and stockholders' equity | 106,406 | |||
Niagen Bioscience, Inc. (NAGE)
Niagen Bioscience, Inc. (NAGE)